Our top pick for
Seres Therapeutics, Inc is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Seres Therapeutics employs 108 staff and has a trailing 12-month revenue of around USD$23.3 million.
|52-week range||USD$2.52 - USD$38.5|
|50-day moving average||USD$24.2682|
|200-day moving average||USD$27.029|
|Wall St. target price||USD$37.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.866|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$23.3 million|
|Gross profit TTM||USD$-45,636,000|
|Return on assets TTM||-23.27%|
|Return on equity TTM||-115.06%|
|Market capitalisation||USD$1.7 billion|
TTM: trailing 12 months
There are currently 6.0 million Seres Therapeutics shares held short by investors – that's known as Seres Therapeutics's "short interest". This figure is 14.3% down from 7.0 million last month.
There are a few different ways that this level of interest in shorting Seres Therapeutics shares can be evaluated.
Seres Therapeutics's "short interest ratio" (SIR) is the quantity of Seres Therapeutics shares currently shorted divided by the average quantity of Seres Therapeutics shares traded daily (recently around 932642.56651017). Seres Therapeutics's SIR currently stands at 6.39. In other words for every 100,000 Seres Therapeutics shares traded daily on the market, roughly 6390 shares are currently held short.
However Seres Therapeutics's short interest can also be evaluated against the total number of Seres Therapeutics shares, or, against the total number of tradable Seres Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seres Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Seres Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.1109% of the tradable shares (for every 100,000 tradable Seres Therapeutics shares, roughly 111 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Seres Therapeutics.
Find out more about how you can short Seres Therapeutics stock.
We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $2.52 up to $38.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 3.9989. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.